Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study

Kiros, Teklehaimanot; Taye, Abebe; Workineh, Lemma; Eyayu, Tahir; Damtie, Shewaneh; Hailemichael, Wasihun; Tiruneh, Tegenaw

doi:10.1016/j.heliyon.2022.e10169

Cited by 3 publications

(4 citation statements)

References 65 publications

(150 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of virological non-suppression was comparable with studies conducted in various places in Ethiopia: 8.3% at TASH [28], 10.24% in the North Shoa Zone [29], 11.8% in Gondar [30], 12.2% at Delgi Hospital [10], 12% in southern Ethiopia [31], and 10.5% in a study conducted in Dar Es Salaam, Tanzania [32]. Virological non-suppression, however, was lower than that reported from Kenya (24%) [33] and Cameroon (23.2%) [34].…”

Section: Discussionsupporting

confidence: 82%

“…The estimated pooled prevalence of virological non-suppression among PLHIV in sub-Saharan Africa is 17.25% [ 6 ]. Nevertheless, the degree of virological non-suppression varies across nations and study populations, with 34% in central Tanzania [ 7 ] and 9–17% in various parts of Ethiopia—9% in Adama [ 8 ], 11% in Jimma [ 9 ], 12.2% in Delgi [ 10 ], 12.5% in the Amhara region [ 11 ], 14.5% in Adigrat [ 12 ], and 16.6% in Sekota [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Virological Non-Suppression among Newly Diagnosed HIV-Positive Individuals on Dolutegravir-Based Antiretroviral Treatment in Eastern Ethiopia: Follow-Up Study

Gemechu,

Mihret,

Atire

et al. 2023

TropicalMed

View full text Add to dashboard Cite

There have been limited studies linking baseline factors, including the viral load (VL) test, with virological non-suppression since the introduction of dolutegravir (DTG)-based regimens as first-line antiretroviral treatment (ART) in Ethiopia. This study aimed to identify baseline factors associated with virological non-suppression between October 2020 and July 2022. A follow-up study was conducted in eastern Ethiopia among newly diagnosed people living with HIV (PLHIV). A questionnaire and a checklist were used to collect the data. Five milliliters of venous blood were obtained at baseline and six months to determine the VL. A VL test was performed using the Abbott RealTime HIV-1 assay. To determine predictors of virological non-suppression, bivariate and multivariate logistic regression analyses were used. There were 235 PLHIV enrolled, 70.6% of whom were female, with a mean age of 33.9 years. Of the 161 retained on ART, virological non-suppression was 8.7% at six months. Baseline predictors of virological non-suppression were age ≤ 30 years, a history of substance use, and a VL greater than 4-log10 copies/mL. In this cohort, virological non-suppression was found to be optimal but still lagged slightly behind the third 95%–target. Thus, targeted interventions, the introduction of baseline VL testing to improve treatment outcomes, and fostering the attainment of UNAIDS 95–95–95 targets are recommended. Furthermore, broader research is recommended to explore the reasons for virological non-suppression in the study area.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Virological Non-Suppression among Newly Diagnosed HIV-Positive Individuals on Dolutegravir-Based Antiretroviral Treatment in Eastern Ethiopia: Follow-Up Study

Gemechu,

Mihret,

Atire

et al. 2023

TropicalMed

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…The effectiveness of treatment depends on factors like viral resistance, drug interactions, and individual preferences. Generic versions of HAART have made it more accessible, while advancements in antiretroviral therapy have led to more effective medications [4,5].Approximately 25.6 million (over 80%) of the 39 million HIV-affected individuals worldwide are from the WHO Africa region at the end of 2022, including 1.8 million children. The UNAIDS aim of 95% coverage by 2025 is still unrealistic despite rising coverage [6].…”

mentioning

confidence: 99%

A Retrospective Study on Virological Recovery Patterns and Factors Associated with HIV Viral Treatment Using Highly Active Anti-Retro viral Therapy in Public Health Facilities in Tigray, Northern Ethiopia

Teame,

Tilahun,

Gebreyohannes

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Viral load monitoring is crucial for identifying treatment failure in HIV/AIDS patients, as low viremia is essential for public health as HIV cannot spread undetectable. This study aimed to assess the sustained virological recovery rate and potential factors affecting HIV patients in Tigray, Northern Ethiopia, receiving combination treatment. Methods HIV patients receiving highly active anti-retroviral therapy (HAART) were the subject of a retrospective investigation. Using a standardized checklist, data was taken from the Tigray Health Bureau database and aligned with data from the Tigray Health Research Institute (THRI). SPSS version 25.0 was used to analyze the data. The correlations between each factor and the categorical outcome variables were evaluated using Pearson's χ2. In order to determine the determinants impacting virological recovery, multivariate logistic regression analyses were performed. Significant relationship levels were established at p < 0.05. Results 7689 HIV patients with a mean age of 43 ± 13 years were recruited on HAART with female predominance 64.4% with 95% CI: 58.3–76.3. At enrollment to ART sizable portion of the research participants 43.7% and 38% were in the productive age ranges of 16–30 and 31–45 years old respectively. The overall virological recovery was 90.9% with significant variations among male and female participants 4.24 (2.97–6.03) with (P < 0.001). Predictors for persistent virological recovery were identified based on baseline viral load, baseline CD4 count, current and baseline age, lost to follow-ups, adherence, and WHO clinical presentations. Conclusion Male participants showed less recovery, with high baseline CD4 count, long therapy stays, and suppressed viral load being key predictors. Regular assessment of treatment response patterns and drug list combinations is crucial for HIV virological recovery. Early enrollment in HAART, tailored interventions, baseline viral load monitoring, longitudinal studies, and gene sequencing are crucial for virological recovery and identifying genetic factors contributing to treatment resistance.

show abstract

Application of parametric survival analysis to women patients with breast cancer at Jimma University Medical Center

Tasfa Marine,

Mengistie

2023

BMC Cancer

View full text Add to dashboard Cite

Public health systems in both industrialized and undeveloped countries continue to struggle with the worldwide problem of breast cancer. In sub-Saharan African countries, notably Ethiopia, it is the form of cancer that strikes women the most commonly. Despite the extreme difficulties, the causes of mortality in Ethiopia have not yet been identified. In addition, little study has been done in this area. Therefore, the major objective of this analysis was to pinpoint the factors that were most responsible for the decreased life expectancy of breast cancer patients at the University of Jimma Medical Center. 552 women who had been treated for breast cancer at Jimma University Medical Center between October 2018 and December 2022 were included in this study, which used a retrospective cohort study design and five-year follow-up data. The most frequent and widely used test for comparing the probability of survival curves between several categorical independent variables was the log-rank test. Next, semi-parametric methods for multivariable analysis using the Cox proportional hazards model were used. Furthermore, a parametric strategy that includes fully parametric survival models better achieves the goal of the analysis. Among covariate, age of patient (ϕ = 254.06; 95% CI (3.95, 7.13), P-value = 0.000), patient live in urban (ϕ = 0.84; 95% CI (-0.35,-0.00), P-value = 0.047), preexisting comorbidity (ϕ = 2.46; 95% CI (0.39, 1.41), P-value = 0.001), overweight women cancer patient (ϕ = 0.05; 95% CI(-4.41,-1.57), P-value = 0.000, positive Axillary Node status cancer patient (ϕ = 0.04; 95% CI(-4.45,-1.88), P-value = 0.000), both surgery and chemotropic baseline treatment patient (ϕ = 0.53; 95% CI(-1.12,-0.16), P-value = 0.009) significantly affected the survival of women breast cancer. Age of breast cancer patient, patient education level, place of residence, marital status, pre-existing comorbidity, axillary node status, estrogen receptor, tumor size, body mass index at diagnosis, stage of cancer, and baseline treatment were found to have a significant effect on time to survive for women with breast cancer at the University of Jimma Medical Center, Oromia region, Ethiopia. However, the covariate histologic grade, number of positive lymph nodes involved, and type of hormone used were insignificant to the survival of breast cancer patients.

show abstract

Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study

Cited by 3 publications

References 65 publications

Virological Non-Suppression among Newly Diagnosed HIV-Positive Individuals on Dolutegravir-Based Antiretroviral Treatment in Eastern Ethiopia: Follow-Up Study

Virological Non-Suppression among Newly Diagnosed HIV-Positive Individuals on Dolutegravir-Based Antiretroviral Treatment in Eastern Ethiopia: Follow-Up Study

A Retrospective Study on Virological Recovery Patterns and Factors Associated with HIV Viral Treatment Using Highly Active Anti-Retro viral Therapy in Public Health Facilities in Tigray, Northern Ethiopia

Application of parametric survival analysis to women patients with breast cancer at Jimma University Medical Center

Contact Info

Product

Resources

About